Cargando…

Comprehensive analysis for the immune related biomarkers of platinum-based chemotherapy in ovarian cancer

BACKGROUND: Ovarian cancer (OC) is one of the most lethal gynecological malignancies. This study aimed to identify biomarkers that were sensitive to platinum-based chemotherapeutic agents and can be used in immunotherapy and explore the importance of their mechanisms of action. METHODS: RNA-seq prof...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jiao, Liu, Yaoyao, Yang, Chunjiao, Liu, Jingjing, Hao, Jiaxin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458992/ https://www.ncbi.nlm.nih.gov/pubmed/37619523 http://dx.doi.org/10.1016/j.tranon.2023.101762

Ejemplares similares

Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer
por: Yang, Ling, et al.
Publicado: (2022)

miR-206 as a prognostic and sensitivity biomarker for platinum chemotherapy in epithelial ovarian cancer
por: Yu, Xiaotang, et al.
Publicado: (2020)

Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells
por: Mikuła-Pietrasik, Justyna, et al.
Publicado: (2018)

ADAMTS16 mutations sensitize ovarian cancer cells to platinum-based chemotherapy
por: Yasukawa, Maya, et al.
Publicado: (2016)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer
por: Compadre, Amanda J., et al.
Publicado: (2023)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Efficacy and Safety of Platinum-Based Chemotherapy for Ovarian Cancer During Pregnancy: A Systematic Review and Meta-Analysis
por: Pei, Yaping, et al.
Publicado: (2021)

Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer
por: Coffman, Lan G., et al.
Publicado: (2022)

Development and Validation of an Immune-Related Gene-Pair Model of High-Grade Serous Ovarian Cancer After Platinum-Based Chemotherapy
por: Lin, Jiaxing, et al.
Publicado: (2021)

Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival
por: Jernigan, Amelia M., et al.
Publicado: (2013)

Predictive Value of HE4 in Platinum-Based Chemotherapy for Ovarian Cancer: A Systematic Review
por: Han, Yue, et al.
Publicado: (2021)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
por: Della Pepa, Chiara, et al.
Publicado: (2014)

Ovarian cancer resistance to PARPi and platinum-containing chemotherapy
por: Summey, Rebekah, et al.
Publicado: (2022)

Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study
por: Liu, Rong, et al.
Publicado: (2020)

The efficacy and safety of platinum-based chemotherapy for ovarian cancer in pregnancy: A protocol for systematic review and meta-analysis
por: Wang, Bei, et al.
Publicado: (2022)

Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis
por: Tang, Ning, et al.
Publicado: (2017)

Adenylate kinase 2 is a biomarker related to the prognosis of glioma and the immune microenvironment
por: Liu, Zhichen, et al.
Publicado: (2023)

3468 Predictive biomarkers of platinum-based chemotherapy response in Puerto Rican Hispanics with high-grade serous ovarian cancer.
por: Reyes-Gonzalez, Jeyshka M., et al.
Publicado: (2019)

ZNF76 predicts prognosis and response to platinum chemotherapy in human ovarian cancer
por: Hua, Tian, et al.
Publicado: (2021)

Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer
por: Wen, Hao, et al.
Publicado: (2022)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]
Publicado: (2014)

Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancer
por: Nara, Katsuhiko, et al.
Publicado: (2023)

DOCK4 Is a Platinum-Chemosensitive and Prognostic-Related Biomarker in Ovarian Cancer
por: Zhao, Qianqian, et al.
Publicado: (2021)

Cross-validation of genes potentially associated with neoadjuvant chemotherapy and platinum-based chemoresistance in epithelial ovarian carcinoma
por: Zhang, Kai, et al.
Publicado: (2020)

Biomarking and Induction of Apoptosis in Ovarian Cancer Using Bifunctional Polyethyleneimine-Caged Platinum Nanoclusters
por: Zhang, Mengjun, et al.
Publicado: (2022)

Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer
por: Sassu, Carolina Maria, et al.
Publicado: (2021)

Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
por: Zhu, Yunshu, et al.
Publicado: (2020)

Corrigendum: Biomarking and induction of apoptosis in ovarian cancer using bifunctional polyethyleneimine-caged platinum nanoclusters
por: Zhang, Mengjun, et al.
Publicado: (2022)

Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy
por: Glaysher, S, et al.
Publicado: (2010)

Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
por: Zhai, Xiaoyu, et al.
Publicado: (2017)

Serum circSETDB1 is a promising biomarker for predicting response to platinum-taxane-combined chemotherapy and relapse in high-grade serous ovarian cancer
por: Wang, Wei, et al.
Publicado: (2019)

Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy
por: Sun, Jie, et al.
Publicado: (2019)

Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer
por: Indini, Alice, et al.
Publicado: (2021)

Major Clinical Impact of Platinum-Based Chemotherapy in a Patient with a Borderline Ovarian Cancer
por: Chen, Jian, et al.
Publicado: (2009)

BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer
por: Stefansson, Olafur A., et al.
Publicado: (2012)

EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy
por: Chebouti, Issam, et al.
Publicado: (2017)

A panel of three oxidative stress-related genes predicts overall survival in ovarian cancer patients received platinum-based chemotherapy
por: Zhang, Jin, et al.
Publicado: (2018)

Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse
por: Ma, Yana, et al.
Publicado: (2023)

A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis
por: Liu, Yuanzhi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rrjiguof7eohbi0o0m8rdap2bt